[{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ MAX BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"MAX BioPharma \/ MAX BioPharma"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Metaba","highestDevelopmentStatusID":"3","companyTruncated":"MAX BioPharma \/ Metaba"}]

Find Clinical Drug Pipeline Developments & Deals by MAX BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Company is focused on developing oxysterol-based drug candidates targeting bacterial infections like tuberculosis, urinary tract infections, Lyme disease and MRSA.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Metaba

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Oxy210 (oxysterol) is being evaluating in the early-stage clinical trial studies for the treatment of patients suffering from non-alcoholic steatohepatitis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 24, 2024

                          Lead Product(s) : Oxysterol,Inapplicable

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The collaboration focuses on developing Oxy210 (oxysterol), a small-molecule antifibrotic, evaluated in preclinical studies for non-alcoholic steatohepatitis and pulmonary fibrosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 26, 2024

                          Lead Product(s) : Oxysterol,Inapplicable

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Preclinical

                          Recipient : Metaba

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 03, 2020

                          Lead Product(s) : Oxysterol,Inapplicable

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank